Cybin Inc. (HELP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Helus Pharma Inc., formerly known as Cybin Inc., filed a Form 6-K on October 27, 2026, incorporating by reference its news release regarding executive leadership transitions. The company announced ...

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company's newsroom at ...

Cybin (NASDAQ:HELP) outlined plans for two late-stage mental health programs, with top-line data from its Phase III APPROACH study of HLP003 in major depressive disorder expected later in the fourth ...

Shareholders are advised that, at the annual general meeting of Cilo Cybin held today, 7 October 2026, all the resolutions as ...

In compliance with paragraph 6.71 of the Listings Requirements of the JSE Limited, the board of directors of Cilo Cybin (“the ...

Cilo Cybin Holdings Limited notified shareholders that Mr. Ian McFarlane had been appointed as Group Chief Commercial Officer and an executive director of the Company with effect from October 20, 2026 ...

HLP003 has been granted Breakthrough Therapy Designation by the FDA, which makes HLP003 eligible for an expedited review pathway, with the potential to reduce drug development timelines. Helus Pharma ...

As the Spice Girls taught us in the nineties, it’s a lot easier if you tell me what you want, what you really, really want. Last month, the Food ...

Co-founders to step down from executive roles and continue to serve on the Board of Directors Helus Pharma board member, Mark ...